Immunovant Inc (NASDAQ: IMVT) is -35.81% lower on its value in year-to-date trading and has touched a low of $12.72 and a high of $34.47 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IMVT stock was last observed hovering at around $16.15 in the last trading session, with the day’s loss setting it -0.25%.
Currently trading at $15.90, the stock is 6.37% and -8.98% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.12 million and changing -1.55% at the moment leaves the stock -36.43% off its SMA200. IMVT registered -42.16% loss for a year compared to 6-month loss of -46.91%. The firm has a 50-day simple moving average (SMA 50) of $17.4691 and a 200-day simple moving average (SMA200) of $25.012026.
The stock witnessed a 4.61% gain in the last 1 month and extending the period to 3 months gives it a -27.96%, and is 5.51% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.83% over the week and 8.07% over the month.
Immunovant Inc (IMVT) has around 207 employees, a market worth around $2.70B and $0.00M in sales. Distance from 52-week low is 25.00% and -53.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-108.53%).
The EPS is expected to shrink by -49.30% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
269.0 institutions hold shares in Immunovant Inc (IMVT), with institutional investors hold 119.80% of the company’s shares. The shares outstanding are 147.20M, and float is at 68.32M with Short Float at 30.49%. Institutions hold 49.62% of the Float.
The top institutional shareholder in the company is FMR LLC with over 10.48 million shares valued at $276.77 million. The investor’s holdings represent 7.1765 of the IMVT Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 6.51 million shares valued at $171.86 million to account for 4.4561 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.92 million shares representing 3.3652 and valued at over $129.79 million, while ARMISTICE CAPITAL, LLC holds 2.3253 of the shares totaling 3.4 million with a market value of $89.68 million.
Immunovant Inc (IMVT) Insider Activity
The most recent transaction is an insider sale by Stout Jay S, the company’s Chief Technology Officer. SEC filings show that Stout Jay S sold 1,925 shares of the company’s common stock on Apr 23 ’25 at a price of $14.79 per share for a total of $28471.0. Following the sale, the insider now owns 0.21 million shares.
Immunovant Inc disclosed in a document filed with the SEC on Apr 23 ’25 that Geffner Michael (Chief Medical Officer) sold a total of 2,349 shares of the company’s common stock. The trade occurred on Apr 23 ’25 and was made at $14.79 per share for $34742.0. Following the transaction, the insider now directly holds 0.23 million shares of the IMVT stock.
Still, SEC filings show that on Apr 16 ’25, Barnett Eva Renee (Chief Financial Officer) disposed off 2,993 shares at an average price of $14.89 for $44566.0. The insider now directly holds 396,774 shares of Immunovant Inc (IMVT).
